Mitchel A Kling1,2, Dayan B Goodenowe3, Vijitha Senanayake3, Siamak MahmoudianDehkordi4, Matthias Arnold4,5, Tyler J Massaro6, Rebecca Baillie7, Xianlin Han8, Yuk-Yee Leung9, Andrew J Saykin10, Kwangsik Nho10, Alexandra Kueider-Paisley4, Jessica D Tenenbaum11, Li-San Wang9, Leslie M Shaw9, John Q Trojanowski9, Rima F Kaddurah-Daouk4,12,13. 1. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2. Behavioral Health Service, Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA. 3. Prodrome Sciences Inc., Temecula, California, USA. 4. Department of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina, USA. 5. Institute of Bioinformatics and Systems Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. 6. Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA. 7. Rosa & Co LLC, San Carlos, California, USA. 8. University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA. 9. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 10. Department of Radiology and Imaging Sciences and the Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, Indiana, USA. 11. Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA. 12. Duke Institute of Brain Sciences, Duke University, Durham, North Carolina, USA. 13. Department of Medicine, Duke University, Durham, North Carolina, USA.
Abstract
INTRODUCTION: Altered lipid metabolism is implicated in Alzheimer's disease (AD), but the mechanisms remain obscure. Aging-related declines in circulating plasmalogens containing omega-3 fatty acids may increase AD risk by reducing plasmalogen availability. METHODS: We measured four ethanolamine plasmalogens (PlsEtns) and four closely related phosphatidylethanolamines (PtdEtns) from the Alzheimer's Disease Neuroimaging Initiative (ADNI; n = 1547 serum) and University of Pennsylvania (UPenn; n = 112 plasma) cohorts, and derived indices reflecting PlsEtn and PtdEtn metabolism: PL-PX (PlsEtns), PL/PE (PlsEtn/PtdEtn ratios), and PBV (plasmalogen biosynthesis value; a composite index). We tested associations with baseline diagnosis, cognition, and cerebrospinal fluid (CSF) AD biomarkers. RESULTS: Results revealed statistically significant negative relationships in ADNI between AD versus CN with PL-PX (P = 0.007) and PBV (P = 0.005), late mild cognitive impairment (LMCI) versus cognitively normal (CN) with PL-PX (P = 2.89 × 10-5 ) and PBV (P = 1.99 × 10-4 ), and AD versus LMCI with PL/PE (P = 1.85 × 10-4 ). In the UPenn cohort, AD versus CN diagnosis associated negatively with PL/PE (P = 0.0191) and PBV (P = 0.0296). In ADNI, cognition was negatively associated with plasmalogen indices, including Alzheimer's Disease Assessment Scale 13-item cognitive subscale (ADAS-Cog13; PL-PX: P = 3.24 × 10-6 ; PBV: P = 6.92 × 10-5 ) and Mini-Mental State Examination (MMSE; PL-PX: P = 1.28 × 10-9 ; PBV: P = 6.50 × 10-9 ). In the UPenn cohort, there was a trend toward a similar relationship of MMSE with PL/PE (P = 0.0949). In ADNI, CSF total-tau was negatively associated with PL-PX (P = 5.55 × 10-6 ) and PBV (P = 7.77 × 10-6 ). Additionally, CSF t-tau/Aβ1-42 ratio was negatively associated with these same indices (PL-PX, P = 2.73 × 10-6 ; PBV, P = 4.39 × 10-6 ). In the UPenn cohort, PL/PE was negatively associated with CSF total-tau (P = 0.031) and t-tau/Aβ1-42 (P = 0.021). CSF Aβ1-42 was not significantly associated with any of these indices in either cohort. DISCUSSION: These data extend previous studies by showing an association of decreased plasmalogen indices with AD, mild cognitive impairment (MCI), cognition, and CSF tau. Future studies are needed to better define mechanistic relationships, and to test the effects of interventions designed to replete serum plasmalogens.
INTRODUCTION: Altered lipid metabolism is implicated in Alzheimer's disease (AD), but the mechanisms remain obscure. Aging-related declines in circulating plasmalogens containing omega-3 fatty acids may increase AD risk by reducing plasmalogen availability. METHODS: We measured four ethanolamine plasmalogens (PlsEtns) and four closely related phosphatidylethanolamines (PtdEtns) from the Alzheimer's Disease Neuroimaging Initiative (ADNI; n = 1547 serum) and University of Pennsylvania (UPenn; n = 112 plasma) cohorts, and derived indices reflecting PlsEtn and PtdEtn metabolism: PL-PX (PlsEtns), PL/PE (PlsEtn/PtdEtn ratios), and PBV (plasmalogen biosynthesis value; a composite index). We tested associations with baseline diagnosis, cognition, and cerebrospinal fluid (CSF) AD biomarkers. RESULTS: Results revealed statistically significant negative relationships in ADNI between AD versus CN with PL-PX (P = 0.007) and PBV (P = 0.005), late mild cognitive impairment (LMCI) versus cognitively normal (CN) with PL-PX (P = 2.89 × 10-5 ) and PBV (P = 1.99 × 10-4 ), and AD versus LMCI with PL/PE (P = 1.85 × 10-4 ). In the UPenn cohort, AD versus CN diagnosis associated negatively with PL/PE (P = 0.0191) and PBV (P = 0.0296). In ADNI, cognition was negatively associated with plasmalogen indices, including Alzheimer's Disease Assessment Scale 13-item cognitive subscale (ADAS-Cog13; PL-PX: P = 3.24 × 10-6 ; PBV: P = 6.92 × 10-5 ) and Mini-Mental State Examination (MMSE; PL-PX: P = 1.28 × 10-9 ; PBV: P = 6.50 × 10-9 ). In the UPenn cohort, there was a trend toward a similar relationship of MMSE with PL/PE (P = 0.0949). In ADNI, CSF total-tau was negatively associated with PL-PX (P = 5.55 × 10-6 ) and PBV (P = 7.77 × 10-6 ). Additionally, CSF t-tau/Aβ1-42 ratio was negatively associated with these same indices (PL-PX, P = 2.73 × 10-6 ; PBV, P = 4.39 × 10-6 ). In the UPenn cohort, PL/PE was negatively associated with CSF total-tau (P = 0.031) and t-tau/Aβ1-42 (P = 0.021). CSF Aβ1-42 was not significantly associated with any of these indices in either cohort. DISCUSSION: These data extend previous studies by showing an association of decreased plasmalogen indices with AD, mild cognitive impairment (MCI), cognition, and CSF tau. Future studies are needed to better define mechanistic relationships, and to test the effects of interventions designed to replete serum plasmalogens.
Authors: Mark Mapstone; Amrita K Cheema; Massimo S Fiandaca; Xiaogang Zhong; Timothy R Mhyre; Linda H MacArthur; William J Hall; Susan G Fisher; Derick R Peterson; James M Haley; Michael D Nazar; Steven A Rich; Dan J Berlau; Carrie B Peltz; Ming T Tan; Claudia H Kawas; Howard J Federoff Journal: Nat Med Date: 2014-03-09 Impact factor: 53.440
Authors: Ernst J Schaefer; Vanina Bongard; Alexa S Beiser; Stefania Lamon-Fava; Sander J Robins; Rhoda Au; Katherine L Tucker; David J Kyle; Peter W F Wilson; Philip A Wolf Journal: Arch Neurol Date: 2006-11
Authors: Giuseppe Astarita; Kwang-Mook Jung; Nicole C Berchtold; Vinh Q Nguyen; Daniel L Gillen; Elizabeth Head; Carl W Cotman; Daniele Piomelli Journal: PLoS One Date: 2010-09-08 Impact factor: 3.240
Authors: Sandip Ray; Markus Britschgi; Charles Herbert; Yoshiko Takeda-Uchimura; Adam Boxer; Kaj Blennow; Leah F Friedman; Douglas R Galasko; Marek Jutel; Anna Karydas; Jeffrey A Kaye; Jerzy Leszek; Bruce L Miller; Lennart Minthon; Joseph F Quinn; Gil D Rabinovici; William H Robinson; Marwan N Sabbagh; Yuen T So; D Larry Sparks; Massimo Tabaton; Jared Tinklenberg; Jerome A Yesavage; Robert Tibshirani; Tony Wyss-Coray Journal: Nat Med Date: 2007-10-14 Impact factor: 53.440
Authors: Dallas P Veitch; Michael W Weiner; Paul S Aisen; Laurel A Beckett; Charles DeCarli; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Susan M Landau; John C Morris; Ozioma Okonkwo; Richard J Perrin; Ronald C Petersen; Monica Rivera-Mindt; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; Duygu Tosun; John Q Trojanowski Journal: Alzheimers Dement Date: 2021-09-28 Impact factor: 16.655
Authors: Eylan Yutuc; Alison L Dickson; Manuela Pacciarini; Lauren Griffiths; Paul R S Baker; Lisa Connell; Anders Öhman; Lars Forsgren; Miles Trupp; Sílvia Vilarinho; Youssef Khalil; Peter T Clayton; Sinan Sari; Buket Dalgic; Philip Höflinger; Ludger Schöls; William J Griffiths; Yuqin Wang Journal: Anal Chim Acta Date: 2021-02-04 Impact factor: 6.558
Authors: Elena Leoni Theiss; Lea Victoria Griebsch; Anna Andrea Lauer; Daniel Janitschke; Vincent Konrad Johannes Erhardt; Elodie Christiane Haas; Konstantin Nicolas Kuppler; Juliane Radermacher; Oliver Walzer; Dorothea Portius; Heike Sabine Grimm; Tobias Hartmann; Marcus Otto Walter Grimm Journal: Cells Date: 2022-08-18 Impact factor: 7.666
Authors: Dayan B Goodenowe; Jonathan Haroon; Mitchel A Kling; Margaret Zielinski; Kennedy Mahdavi; Barshen Habelhah; Leah Shtilkind; Sheldon Jordan Journal: Front Cell Dev Biol Date: 2022-07-06